AV Awarded $20 Million Contract to Advance Ceramic Materials Research for the U.S. Air Force and Space Force

AV Awarded $20 Million Contract to Advance Ceramic Materials Research for the U.S. Air Force and Space Force

AV and AFRL researchers will develop advanced ceramics, composites, and modeling techniques for extreme aerospace environments

ARLINGTON, Va.–(BUSINESS WIRE)–
AeroVironment, Inc. (“AV”) (NASDAQ: AVAV), a global leader in defense technology innovation, today announced it has been awarded a $20 million Ceramics Advanced Materials and Processes (CAMP) contract by the Air Force Research Laboratory (AFRL) Materials and Manufacturing Directorate to advance next-generation ceramic and ceramic matrix composite materials (CMCs) for extreme aerospace and defense applications supporting the U.S. Air and Space Forces.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528311369/en/

AV researchers and AFRL engineers will collaborate at Wright-Patterson Air Force Base to advance next-generation ceramic materials and aerospace manufacturing technologies supporting future Air and Space Force missions. (Photo: AV)

AV researchers and AFRL engineers will collaborate at Wright-Patterson Air Force Base to advance next-generation ceramic materials and aerospace manufacturing technologies supporting future Air and Space Force missions. (Photo: AV)

Under the 39-month contract, AV’s materials experts will partner with AFRL scientists and engineers at Wright-Patterson Air Force Base in Dayton, Ohio, to accelerate development, field advanced capabilities faster, and strengthen mission readiness while reducing lifecycle costs. The team will apply advanced additive manufacturing, three-dimensional (3D) printing, and sensor integration techniques to create lightweight, thermally resilient structures—such as high speed aerodynamic vehicles, turbine engines, rocket propulsion systems, transparent armor, thermal-protection tiles, and nozzle extensions—designed to perform in the most extreme environments.

“CAMP represents a vital investment in technologies that will preserve America’s advantage across air and space domains,” said Johnathan Jones, Senior Vice President of Cyber and Mission Solutions at AV. “By advancing the next generation of high-temperature materials and manufacturing processes, we will deliver capabilities that enhance mission readiness, extend operational endurance, and strengthen the technological superiority of our Air and Space Forces.”

Research conducted under the CAMP program will advance next-generation ceramics through precursor synthesis and processing, novel fabrication and design methods, microstructural characterization, and advanced modeling to better predict performance and durability. The effort will span the full lifecycle of material innovation, integrating embedded sensors for real-time health monitoring and developing multifunctional ceramics for aerospace, space, energy, and defense applications—from satellite propulsion and helicopter armor to ultra-efficient energy systems and advanced sensors.

“Collaborations with our customers are at the heart of what we do,” said Dr. John Hogan, Vice President of Defense and Interagency Service at AV. “Through the CAMP program, we’re not just developing better ceramics—we’re creating the materials foundation for the future of flight and space operations. This collaboration ensures our research directly supports mission readiness, durability, and operational effectiveness for the Air and Space Forces.”

About AV

AeroVironment (“AV”) (NASDAQ: AVAV) is a defense technology leader delivering integrated capabilities across air, land, sea, space, and cyber. The Company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities—built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo™, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. For more information, visit www.avinc.com.

Safe Harbor Statement

Certain statements in this press release may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, and assumptions that involve risks and uncertainties, which could cause actual results to differ materially. Factors that may cause such differences include, but are not limited to, our ability to perform under existing contracts and obtain new ones; regulatory changes; competitor activities; market growth; product development challenges; and general economic conditions. For a more detailed discussion of these risks, please refer to AeroVironment’s filings with the Securities and Exchange Commission. We undertake no obligation to update forward-looking statements as a result of new information or future events.

Media Contact:

BJ Koubaroulis

[email protected]

703.718.4060

Investor Contact:

Denise Pacioni

[email protected]

805.795.4108

KEYWORDS: United States North America Virginia Ohio

INDUSTRY KEYWORDS: Software Defense Military Technology Air Aerospace Transport Manufacturing

MEDIA:

Photo
Photo
AV researchers and AFRL engineers will collaborate at Wright-Patterson Air Force Base to advance next-generation ceramic materials and aerospace manufacturing technologies supporting future Air and Space Force missions. (Photo: AV)
Logo
Logo

Supermicro Collaborates with Taiwanese Authorities to Prevent Illicit Diversion of Server Technology

PR Newswire

SAN JOSE, Calif., May 28, 2026 /PRNewswire/ — Super Micro Computer, Inc. (NASDAQ: SMCI), an AI, Enterprise, Storage, and 5G/Edge Total IT Solution Provider featuring Data Center Building Block Solutions® (DCBBS), today issued the following statement regarding recent collaboration with the Taiwanese authorities to prevent illicit diversion of server technology:

Supermicro is committed to protecting our advanced technologies and intellectual property, and we are proud to have worked closely with Taiwanese authorities on the recent event, helping to prevent the illicit diversion of our highly sought-after systems into the restricted China market. Our collaboration with authorities in Taiwan resulted in the arrest of three suspects and the seizure of 50 servers that had been deceptively acquired after being sold by Supermicro to an authorized reseller. We thank local law enforcement and legal officials for their vigilance and professionalism.

The initial transaction – Supermicro’s sale of products to an authorized reseller – followed a rigorous vetting and review process that exceeded applicable government requirements. This case highlights the challenges that can arise when products are resold through multiple downstream parties beyond direct manufacturer control. It also underscores the importance of continued collaboration across industry and government to strengthen safeguards, enhance supply chain visibility, and facilitate the enforcement of export control laws. Supermicro will continue to cooperate with law enforcement and government officials in the United States, Taiwan and other jurisdictions to ensure our technology is distributed as lawfully intended.

About Super Micro Computer, Inc.

Supermicro (NASDAQ: SMCI) is a global leader in Application-Optimized Total IT Solutions. Founded and operating in San Jose, California, Supermicro is committed to delivering first-to-market innovation for Enterprise, Cloud, AI, and 5G Telco/Edge IT Infrastructure. We are a Total IT Solutions provider with server, AI, storage, IoT, switch systems, software, and support services. Supermicro’s motherboard, power, and chassis design expertise further enables our development and production, enabling next-generation innovation from cloud to edge for our global customers. Our products are designed and manufactured in-house (in the US, Taiwan, and the Netherlands), leveraging global operations for scale and efficiency and optimized to improve TCO and reduce environmental impact (Green Computing). The award-winning portfolio of Server Building Block Solutions® allows customers to optimize for their exact workload and application by selecting from a broad family of systems built from our flexible and reusable building blocks that support a comprehensive set of form factors, processors, memory, GPUs, storage, networking, power, and cooling solutions (air-conditioned, free air cooling or liquid cooling).

Supermicro, Server Building Block Solutions, and We Keep IT Green are trademarks and/or registered trademarks of Super Micro Computer, Inc.

All other brands, names, and trademarks are the property of their respective owners.

Contacts:

Investor Contact:
[email protected]

Media Contact:
[email protected]

 

Cision View original content:https://www.prnewswire.com/news-releases/supermicro-collaborates-with-taiwanese-authorities-to-prevent-illicit-diversion-of-server-technology-302784510.html

SOURCE Super Micro Computer, Inc.

Beautiful and Fire-Smart: How Firescaping Can Help Reduce Wildfire Risk Around the Home

PR Newswire

During Wildfire Preparedness Month, Mercury Insurance shares practical landscaping strategies that can help homeowners create more resilient outdoor spaces

LOS ANGELES, May 28, 2026 /PRNewswire/ — As communities across wildfire-prone regions continue preparing for another active fire season, Mercury Insurance (NYSE/NYSE TX: MCY) is encouraging homeowners to rethink traditional landscaping through the growing practice of “firescaping,” a wildfire-conscious approach to yard design that can help reduce ignition risk while maintaining curb appeal.

Research from the Insurance Institute for Business & Home Safety (IBHS), CAL FIRE, and wildfire safety experts continues to show that a home’s immediate surroundings can play a major role in whether it survives a wildfire. Embers, which can travel miles ahead of an active fire, are one of the leading causes of home ignitions and often ignite dry vegetation, combustible mulch, fencing, and debris surrounding a structure.

“Many homeowners think wildfire mitigation means removing everything from their yard, but firescaping is really about making smarter choices around how outdoor spaces are designed and maintained,” said Holly Sacks, Director, Portfolio Underwriting and CAT Management at Mercury Insurance. “Small landscaping changes can help reduce opportunities for embers to ignite around the home while still creating an attractive and enjoyable outdoor environment.”

IBHS and CAL FIRE guidance emphasize the importance of reducing combustible materials closest to the home, particularly within the first five feet surrounding a structure, often referred to as “Zone 0.” This area is considered critical because embers frequently accumulate near foundations, vents, fences, decks, and landscaping features during wildfire events.

To help homeowners create more fire-conscious landscapes, Mercury Insurance recommends several firescaping strategies supported by wildfire preparedness experts:

Create a noncombustible zone closest to the home

CAL FIRE recommends minimizing combustible materials within the first five feet around a structure. Gravel, stone, pavers, and concrete surfaces can help reduce ignition opportunities compared to bark, wood mulch, or dry vegetation.

Choose plants carefully

While no plant is completely fireproof, IBHS and wildfire experts recommend selecting plants with higher moisture content and lower levels of oils or resins. Proper spacing and ongoing maintenance are equally important.

Reduce fuel continuity in landscaping

Dense clusters of shrubs and vegetation can allow fire to spread more easily across a property. Spacing plants apart and avoiding continuous rows of vegetation can help slow fire movement.

Eliminate ladder fuels

Shrubs, brush, and lower tree branches can create pathways that allow ground fires to climb into trees and spread more rapidly. Trimming lower branches and maintaining vertical spacing between plants can help reduce this risk.

Use hardscaping to create natural breaks

Stone walkways, retaining walls, patios, and gravel paths can serve as attractive design features while also helping interrupt the spread of fire across a property.

Keep outdoor areas maintained year-round

Leaves, pine needles, dead vegetation, and debris should be removed regularly from gutters, under decks, and around landscaping features where embers may collect.

According to IBHS research, homes located in the same neighborhood can experience dramatically different outcomes during a wildfire depending on surrounding conditions, maintenance, and mitigation efforts.

“Preparedness does not have to come at the expense of curb appeal,” Sacks added. “Firescaping is about creating a safer, more resilient property while still maintaining outdoor spaces homeowners can enjoy.”

For more wildfire preparedness information and safety resources, visit [Mercury resource link].

About Mercury Insurance

Mercury Insurance (NYSE: MCY) is a multiple-line insurance carrier predominantly offering personal auto, homeowners, renters and commercial insurance through a network of independent agents in Arizona, California, Georgia, Illinois, Nevada, New Jersey, New York, Oklahoma, Texas and Virginia, as well as auto insurance in Florida. Mercury writes other lines of insurance in various states, including commercial, business owners and business auto, landlord, home-sharing, ride-hailing and mechanical protection insurance.

Since 1962, Mercury has provided customers with tremendous value for their insurance dollar by pairing ultra-competitive rates with excellent customer service, through more than 4,200 employees and a network of more than 6,340 independent agents in 11 states. Mercury has earned an “A” rating from A.M. Best, as well as “Best Auto Insurance Company” designations from Forbes and Insure.com. For more information visit www.MercuryInsurance.com or follow the company on LinkedIn, Instagram or Facebook.

Media interested in receiving updates from Mercury can learn more at the

Mercury Newsroom

.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/beautiful-and-fire-smart-how-firescaping-can-help-reduce-wildfire-risk-around-the-home-302784364.html

SOURCE Mercury Insurance Services, LLC

TCW Steel City Serves as Lead Arranger, Administrative Agent on Wynnchurch Capital, LP, Acquisition of NABRICO Marine Products

PR Newswire

PITTSBURGH, May 28, 2026 /PRNewswire/ — TCW Steel City (“Steel City”) today announced it served as lead arranger and administrative agent for Wynnchurch Capital LP’s acquisition of NABRICO Marine Products, formerly Arcosa Marine Products, Inc., from Arcosa Inc. (NYSE: ACA).

Headquartered in Covington, Louisiana, NABRICO is a leading manufacturer of hopper barges, tank barges, fiberglass covers and marine components serving the inland waterway transportation market.

“We are pleased to support Wynnchurch Capital in its acquisition of NABRICO Marine Products,” said Walt Hill on behalf of Steel City. “This transaction reflects our continued focus on providing flexible, reliable financing solutions to leading businesses with strong market positions and long-term growth potential.”

“Steel City was a strong partner throughout this transaction,” said Mike MacKay, principal at Wynnchurch Capital. “The team executed an efficient process and brought a thoughtful, solutions-oriented approach at each stage. We value their partnership and look forward to working together again.”

About Wynnchurch Capital, LP

Wynnchurch Capital, LP, headquartered in the Chicago suburb of Rosemont, Illinois, with an affiliate in Canada, was founded in 1999 and is a leading middle-market private equity investment firm. Wynnchurch’s strategy is to partner with middle market companies in the United States and Canada that possess the potential for substantial growth and profit improvement. 

Wynnchurch manages a number of private equity funds with $9.1 billion of assets under management and specializes in recapitalizations, growth capital, management buyouts, corporate carve-outs, and restructurings. Recently, Wynnchurch acquired Charter Industries, a leading provider of edgebanding and complementary products. Other recent investments include: Astro Shapes, a leading manufacturer of custom aluminum extrusions; Principal Industries, a leading provider of LED components and engineered assemblies; and ORS Nasco, North America’s largest pure wholesaler of industrial MRO supplies. For more information, please visit: https://www.wynnchurch.com.

About TCW Steel City

Steel City is a private credit platform that combines the experience and resources of PNC Bank, the seventh largest commercial banking institution in the U.S. by domestic assets, with TCW Private Credit, which has a 25-year track record in direct lending. The collaboration leverages nearly two decades of shared execution between the firms, including over 60+ joint transactions completed prior to the launch of Steel City. The strategy primarily focuses on senior secured, first lien cash flow loans, with additional capabilities in asset based and specialty financing structures, to sponsored and non-sponsored borrowers across a broad range of industries in the core middle market. Steel City operates as a separate platform with a dedicated team staffed by both PNC Bank and TCW.

The information contained herein may include preliminary information and/or “forward-looking statements.” Due to numerous factors, actual events may differ substantially from those presented. Neither TCW nor PNC Bank assumes a duty to update any forward-looking statements or opinions in this document. Any opinions expressed herein are current only as of the time made and are subject to change without notice. Past performance is no guarantee of future results

Investment vehicles within the Steel City private credit platform are advised by TCW PT Management Company LLC, an SEC registered investment adviser wholly owned by TCW Asset Management Company, an SEC registered investment adviser and sub-advised by PNC Steel City Advisors, LLC, an SEC registered investment adviser wholly owned by PNC Bank, National Association (“PNC Bank”). The ability of PNC Bank and its affiliates to provide products and services to borrowers receiving extensions of credit from Steel City is subject to applicable legal and regulatory restrictions.   In connection with such activities, PNC Bank and/or an affiliate thereof may receive fees, investment returns and other economic benefits which may create a conflict of interest.

Not FDIC Insured-Not Bank Guaranteed- Not a Deposit -Not Insured by Any Federal Government Agency-May Lose Value

©2026 TCW and The PNC Financial Services Group, Inc. All rights reserved. TCW is a registered mark of The TCW Group, Inc. PNC and PNC Bank are registered marks of The PNC Financial Services Group, Inc.  Steel City and Steel City Private Credit are trademarks of The PNC Financial Services Group, Inc.

CONTACT:
Nicole Lininger
(724) 601-0337
[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tcw-steel-city-serves-as-lead-arranger–administrative-agent-on-wynnchurch-capital-lp-acquisition-of-nabrico-marine-products-302783947.html

SOURCE TCW Steel City

CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA

PR Newswire

Commercialization in China through partnership with SciClone Pharmaceuticals

Expands access to potentially life-saving antibiotic 
in the world’s second-largest pharmaceutical market

NASHVILLE, Tenn., May 28, 2026 /PRNewswire/ — Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation focused biopharmaceutical company, today announced the launch of its Vibativ® (telavancin) injection in China, following regulatory approval and a strategic partnership with SciClone Pharmaceuticals (Holdings) Limited.

The launch follows a previously announced agreement granting SciClone exclusive rights to register, promote and distribute telavancin, injection across China. The product’s approval by China’s National Medical Products Administration (NMPA) enables SciClone to commercialize the product in one of the world’s largest and fastest-growing pharmaceutical markets.

Telavancin is a patented, FDA-approved injectable anti-infective that serves as a potentially life-saving treatment for patients with serious bacterial infections, including hospital-acquired and ventilator-associated pneumonia. The therapy is designed to treat infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA). Vibativ addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

“Launching telavancin in China marks a significant milestone in advancing our mission of providing unique products that improve the quality of patient care,” said A.J. Kazimi, Cumberland Pharmaceuticals CEO. “Through our partnership with SciClone, we are expanding access to this important therapy and providing physicians in China with a valuable new option to treat serious, difficult-to-manage infections.”

Antimicrobial resistance continues to be a critical global health challenge, reducing the effectiveness of many existing antibiotics and increasing the need for innovative treatments. Telavancin was specifically designed to address resistant pathogens, offering potent activity against difficult-to-treat infections.

Mr. Zhao Hong, President and Chief Executive Officer of SciClone Pharmaceuticals, stated, “The successful launch of telavancin for injection in China represents another important milestone for SciClone Pharmaceuticals in the anti-infective field. Currently, MRSA remains a serious challenge and poses a significant clinical threat, particularly in respiratory tract infections, especially those that are hospital-acquired. With its unique dual bactericidal mechanism, broad antibacterial spectrum, and once-daily dosing regimen, telavancin offers an important new anti-infective option for Chinese patients with severe infections, delivering both improved efficacy and clinical convenience. Looking ahead, SciClone Pharmaceuticals will continue to focus on severe infection and oncology, address unmet medical needs, and accelerate the launch of more innovative products in China to contribute to the ‘Healthy China 2030’ initiative.”


About Vibativ



®

Vibativ® (telavancin) injection was discovered in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA. It is a once-daily, injectable lipoglycopeptide antibiotic with in vitro potency, bactericidal activity within six hours and penetration into target infection sites. The drug is approved in the U.S. and Saudi Arabia for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of S. aureus when alternative treatments are not suitable.

In addition, telavancin is approved in the U.S. and Saudi Arabia for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including S. aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains. The product labeling also describes the use of telavancin in treating patients whose pneumonia or skin infection is complicated by concurrent bacteremia. The product’s proven efficacy against difficult-to-treat Gram-positive infections has been demonstrated in several large, multinational registrational studies, which involved one of the largest cohorts of patients with S. aureus infections studied to date. Importantly, these studies demonstrated significantly higher cure rates for telavancin as compared to vancomycin in HABP/VABP due to any single Gram-positive pathogen or S. aureus with vancomycin MIC ≥1 µg/mL. Additionally, there is extensive and well-documented evidence of the drug’s in vitro potency and in vivo activity against a broad collection of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

For full prescribing information, including important safety information, visit www.vibativ.com.


About SciClone Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) is a global biopharmaceutical company with an integrated platform for the development and commercialization of innovative therapies for cancer and severe infection.

With an innovation-driven strategic transformation, SciClone Pharmaceuticals has established a product portfolio with differentiated advantages, including a number of first-in-class and best-in-class potential products / pipelines. Staying true to its original aspiration of “SciClone gives life hope,” SciClone Pharmaceuticals is dedicated to improving patients’ health by providing top-tier health care products and services with global standards of care.

For more information regarding SciClone Pharmaceuticals, please visit: www.sciclone.com.

For SciClone press contacts please reach out to [email protected].


About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late stage product candidates across multiple therapeutic areas with significant unmet medical needs.

For more information, please visit www.cumberlandpharma.com.


FORWARD LOOKING STATEMENTS:

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland’s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company’s intent, belief or expectations, and can be identified by the use of terminology such as “may,” “will,” “expect,” “believe,” “intend,” “plan,” “estimate,” “goal”, “should,” “seek,” “anticipate,” “look forward” and other comparable terms or the negative thereof. As with any business, all phases of Cumberland’s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland’s operation results. These factors include risks and uncertainties related to the strategic transaction, risks related to our ability to develop our pipeline of new product candidates, macroeconomic conditions, including changes in interest rates, inflation, tariffs, competition, an inability of manufacturers to produce Cumberland’s products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company’s control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission (“SEC”), as well as the Company’s other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

 

Cision View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-launch-of-vibativ-in-china-302784350.html

SOURCE Cumberland Pharmaceuticals Inc.

Root Celebrates Back-to-Back Indianapolis 500 Victories Through Partnerships Built on Performance and Innovation

Consecutive Indy 500 wins with two elite racing organizations reinforce Root’s focus on innovation, strategic partnerships, and winning at the highest level

COLUMBUS, Ohio, May 28, 2026 (GLOBE NEWSWIRE) — Root (NASDAQ: ROOT), the leading technology company in car insurance, is celebrating a historic milestone as drivers representing two different Root-sponsored teams, Chip Ganassi Racing and Meyer Shank Racing, captured back-to-back victories at the iconic Indianapolis 500.

After winning the 2025 Indianapolis 500 alongside Chip Ganassi Racing, Root returned to Victory Lane this year with Meyer Shank Racing, marking consecutive Indy 500 victories with two of INDYCAR’s top organizations. This achievement reflects Root’s strategic focus on identifying, selecting, and building deep partnerships with best-in-class organizations that share a commitment to precision, technology, and execution.

“Winning the Indianapolis 500 two years in a row with two different elite organizations is incredibly meaningful for Root,” said Jason Shapiro, SVP of Business Development at Root Insurance. “We continue to align ourselves with organizations that operate at the highest level under pressure, innovate constantly, and never stop pursuing improvement. That data-driven mindset mirrors our approach to building Root’s product and partner network.”

Root has rapidly expanded its partnership ecosystem across automotive, financial services, and independent agent channels, with strategic collaborations serving as a key driver of growth and helping to accelerate access to new customers nationwide. The company’s new writings in the partnership channel nearly tripled in 2025 alone, underscoring the momentum and scale of Root’s expanding distribution strategy.

The company sees its success in motorsports as a validation of its broader business philosophy of partnering with elite operators who challenge convention and deliver results. This partnership approach directly extends to INDYCAR racing, where the demands for precision, speed, teamwork, and constant innovation closely align with how Root uses technology, data, and analytics to build and scale its business.

“Root has become part of our racing family,” said Mike Shank, Co-Owner of Meyer Shank Racing. “They understand that great partnerships are built on trust, alignment, and shared ambition. This Indy 500 win is the ultimate validation of our shared track record of success.”

Beyond race day exposure, Root’s INDYCAR partnerships have strengthened relationships across the automotive and technology spaces while creating opportunities for collaboration with some of the most respected operators, engineers, and executives in professional sports.

“We look for partners that truly understand performance and innovation,” said Chip Ganassi, Owner of Chip Ganassi Racing. “Root has been an outstanding partner because they share our mindset, pushing boundaries, trusting data, and striving to improve every day.”

Root is actively expanding strategic partnerships nationwide as it continues growing its embedded insurance and distribution footprint. These consecutive Indianapolis 500 victories now stand as a powerful example of Root’s ability to identify high-performing partners, invest in innovation, and build relationships designed to win.

About Root, Inc.

Root Insurance is a technology company revolutionizing car insurance through data science and automation. The Root app has reached more than 17 million downloads and has analyzed more than 36 billion miles of driving data to deliver personalized and fair pricing. Root, Inc. (NASDAQ: ROOT) is the parent company of Root Insurance Company.

Root Contacts:

Partnerships:


[email protected]

Media:


[email protected]

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of federal securities laws regarding Root, Inc. These forward-looking statements relate to, among other things, expectations about our future business results. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the company’s control and are difficult to predict. We have based our forward-looking statements on our current expectations, estimates and projections about our industry and our company. We caution that these statements are not guarantees of future performance and you should not rely unduly on them, as they involve risks, uncertainties and assumptions that we cannot predict and many of which are beyond our control. Accordingly, our actual results may differ materially from the future performance that we have expressed or forecast in our forward-looking statements. In accordance with “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we have included in Root’s Form 10-K for the year ended Dec. 31, 2025, and other SEC filings, cautionary language identifying important factors, though not necessarily all such factors, that could cause future outcomes to differ materially from those set forth in the forward-looking statements. Copies of Root’s Form 10-K and other SEC filings are available on the SEC’s website, Root’s website at ir.joinroot.com/investor-relations or by contacting Root’s Investor Relations office.



MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

  • First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria
  • Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapies
  • Preliminary data expected in the second half of 2026

NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 with standard of care (SOC) vs placebo with SOC in patients with severe acute lung injury and critical illness.

The first patient was dosed at First Lviv Territorial Medical Union in Lviv, Ukraine, in collaboration with UNBROKEN Ukraine just days after approval from Ministry of health of Ukraine marking the rapid transition from trial activation to treatment administration in a real-world, high-acuity intensive care environment.

The randomized trial, designated C-1300-02, is evaluating agenT-797 plus standard of care compared with placebo plus standard of care in patients with acute lung injury meeting Global Acute Respiratory Distress Syndrome, or ARDS, criteria. The study is designed to evaluate clinically meaningful ICU outcomes, including survival, ventilator-free days, ICU recovery, and biologic measures associated with treatment activity and immune function.

“This milestone marks the advancement of a potentially new therapeutic paradigm for critical illness,” said Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics. “Patients with severe lung injury and respiratory failure continue to face extraordinarily high mortality despite modern intensive care. These conditions remain among the largest unresolved challenges in medicine, with no approved therapies demonstrated to reduce mortality. agenT-797 was designed for these moments, delivering an immediately available, donor-derived iNKT cell therapy that can be delivered without patient-specific manufacturing, lymphodepletion, or HLA matching. This milestone also demonstrates the practical feasibility of delivering an off-the-shelf cell therapy into a real-world critical care environment. With treatment now underway, we remain focused on efficient study execution and generating preliminary data by second half of 2026.”

Acute lung injury and ARDS remain among the most serious unresolved conditions in critical care, with mortality exceeding 40-50% and no approved therapies shown to reduce mortality.i Critically ill patients often deteriorate because severe lung injury can trigger broader immune dysfunction, including impaired pathogen control, infection susceptibility, and organ dysfunction.

“Patients with severe acute lung injury often deteriorate because inflammatory injury, immune exhaustion, infection risk, and respiratory failure become interconnected,” said Terese Hammond, M.D., Head of R&D at MiNK Therapeutics. “The rapid activation of this trial allows us to evaluate agenT-797 in a real-world, critically ill population where immune restoration may be most meaningful. The study is designed to assess clinically important ICU outcomes, including survival, ventilator-free days, ICU recovery, pathogen control, and secondary infections.”

First Lviv Territorial Medical Union serves a high-acuity critical care population, including patients with severe pneumonia, trauma-associated lung injury, infectious complications, and respiratory failure. Clinical care standards are aligned with modern Western intensive care practices, supporting generation of data intended to inform future regulatory pathways in the United States and Europe.

“Physicians in Ukraine are confronting some of the most severe forms of respiratory failure, trauma, infection, and immune dysfunction seen anywhere in the world,” said Dr. Khrystyna Orlynska, MD, Head of the Department of Anesthesiology and Intensive Care and Principal Investigator. “The initiation of this study provides critically ill patients access to a novel investigational immunotherapy approach and marks the first clinical evaluation of iNKT cell therapy in Ukraine.”

“This study reflects the reality of modern critical care medicine, where severe respiratory failure, infection, trauma, and immune dysfunction frequently converge,” said Demian Kalysh, MD, Anesthesiology, Pulmonary Critical Care and Sub-Investigator. “For physicians caring for patients under these conditions, the ability to evaluate a rapidly deployable off-the-shelf immune restorative therapy in the ICU is both scientifically important and highly meaningful for patients with otherwise limited treatment options.”

The trial has received authorization from the Ukraine Ministry of Health and is supported by an active U.S. IND with US site expansion underway. Preliminary data are expected in the second half of 2026.

About C-1300-02 Trial

The C-1300-02 trial is a randomized Phase 2 study evaluating agenT-797 plus standard of care compared with placebo plus standard of care in adults with acute lung injury and critical illness, including moderate to severe acute hypoxemic respiratory failure, who meet Global ARDS criteria. The study is being initiated at First Lviv Territorial Medical Union in Lviv, Ukraine along with U.S. sites. The trial has received authorization from the Ukraine Ministry of Health, is supported by an active U.S. IND. Preliminary data are expected in the second half of 2026.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic iNKT cell therapies for life-threatening conditions driven by immune dysfunction. The company’s lead program, agenT-797, is being evaluated in acute lung injury and critical illness, with a pipeline that extends across immuno-oncology, transplant medicine, and other settings where dysregulated immunity is a driver of morbidity and mortality. MiNK believes that iNKT cell biology, because of its regulatory role across innate and adaptive immunity, may represent a foundational approach to immune restoration applicable across a broad range of conditions. For more information, visit www.minktherapeutics.com.

About First Lviv Territorial Medical Union and UNBROKEN

First Lviv Territorial Medical Union is one of Ukraine’s largest and most advanced integrated healthcare systems, serving as a regional referral center for western Ukraine. The institution provides comprehensive care across trauma, critical illness, infectious disease, and complex surgery, with specialized capabilities in intensive care and post-acute recovery. Since the onset of the full-scale war, it has been at the forefront of treating both civilians and service members with severe injuries and infection-related complications, operating at a scale and acuity comparable to major Western medical care. For more information, visit First Lviv Territorial Medical Union.

UNBROKEN Ukraine is a nationally recognized medical and rehabilitation ecosystem based in Lviv, dedicated to the treatment and recovery of individuals affected by war. The program integrates acute care, reconstructive surgery, prosthetics, physical and psychological rehabilitation, housing, and long-term reintegration services. Since the start of the full-scale invasion, UNBROKEN has treated more than 24,000 wounded Ukrainians, including children, and has become a leading model for coordinated, multidisciplinary recovery in conflict settings. For more information, visit UNBROKEN Ukraine.

Contacts

Investor Contact: 917-362-1370 | [email protected]
Media Contact: 781-674-4428 | [email protected]

_____________________
References

i  Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients with Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016;315(8):788–800.



You Can Now Find Waldo Hidden Inside Bingo Blitz In Brand New Partnership

PR Newswire

Two iconic worlds of search, discovery and the winning moment come together in a global in-game collaboration

HERZLIYA, Israel, May 28, 2026 /PRNewswire/ — Playtika, a global leader in mobile gaming entertainment and technology, today announces a collaboration between its flagship title Bingo Blitz and Where’s Waldo? in collaboration with Universal Products & Experiences. A globally beloved brand that has remained a familiar presence in homes around the world, Where’s Waldo? is a perfect fit for a game played by a global community of millions.

 

For over 15 years, Bingo Blitz has been at the forefront of the free-to-play bingo category, bringing together players around the world who compete and connect in real time*. Built on social gameplay, rich content, and a genuinely engaged global community, it provides a natural home for a globally recognised brand like Where’s Waldo?.

The Bingo Blitz collaboration introduces a full in-game takeover featuring two Where’s Waldo? inspired rooms set in vibrant, detail-rich environments. While inspired by the excitement of searching for Waldo, the experience remains rooted in classic bingo gameplay, whilst bringing brand new anticipation and recognition into the Bingo Moment.


Lior Itzhak, GM at Bingo Blitz said:

“What makes this collaboration exciting is how naturally the two experiences align. Our players are driven by anticipation, recognition and the excitement of the Bingo Moment. Where’s Waldo? taps into that same feeling – the satisfaction of spotting the right detail at the right moment. Bringing Waldo into Bingo Blitz allows us to build on that shared instinct and offer our players something new, while staying true to what they love.”

Bingo Blitz is available for free download on the App Store and Google Play (in-app purchases are available; for players 21 years of age or older). To follow along, visit Bingo Blitz on Facebook and Instagram.

About Bingo Blitz®

Bingo Blitz is the world’s #1 free-to-play bingo game, enjoyed by a global community of players. Known for its strong social layer, rich content, and innovative features, Bingo Blitz continues to reinvent how people experience bingo by blending familiar gameplay with fresh, engaging moments that bring players together worldwide.

The BINGO BLITZ name and logo are trademarks of Playtika Santa Monica LLC.

*According to Sensor Tower, Bingo Blitz is the world’s most popular free-to-play Bingo game by worldwide downloads across iOS and Google Play, as of 2025.

About Where’s Waldo

First published in 1987, Where’s Waldo? began as a collection of puzzle books created by English illustrator Martin Handford. The books became well-known for the challenge of finding Waldo hidden among detailed double-page illustrations and have been published in more than 30 languages worldwide. Readers are invited to search and find Waldo, recognizable for his iconic wardrobe including black-framed glasses, a red and white striped sweater, and a bobble hat. For nearly 35 years, Waldo’s popularity has continued to transcend beyond books, inspiring television programs, video games, merchandise, comic strips, World Record attempts, events, and more. Where’s Waldo? has become a beloved brand for generations of kids and adults across the globe.

About Universal Products & Experiences

Universal Products & Experiences (UP&E) globally drives the expansion and elevation of NBCUniversal’s iconic collection of brands, intellectual properties, characters, and stories based on the company’s extensive portfolio of properties created by Universal Pictures, Illumination, DreamWorks Animation and NBCUniversal Television and Streaming. The division executes this through innovative physical and digital products, as well as engaging retail and product experiences across our expansive global theme park destinations (for both owned and third-party IP), location-based venues, e-commerce product platforms, and retailers around the world. Along with global brand strategy and creative, UP&E’s lines of business include Consumer Products and Games, along with Theme Parks Products & Retail. UP&E is a division of Universal Destinations & Experiences, part of NBCUniversal, a subsidiary of Comcast Corporation. More information is available at universalproductsexperiences.com.

About Playtika

Playtika Holding Corp. (NASDAQ: PLTK) is a mobile gaming entertainment and technology market leader with a portfolio of multiple game titles. Founded in 2010, Playtika was among the first to offer free-to-play social games on social networks and, shortly after, on mobile platforms. Headquartered in Herzliya, Israel, and guided by a mission to entertain the world through infinite ways to play, Playtika has employees across offices worldwide. For more, visit playtika.com.

Video – https://www.youtube.com/watch?v=KNdio2NiXN8
Photo – https://mma.prnewswire.com/media/2989788/Playtika_Ltd_Wheres_Waldo.jpg
Logo – https://mma.prnewswire.com/media/2905084/5992093/Playtika_Logo.jpg

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/you-can-now-find-waldo-hidden-inside-bingo-blitz-in-brand-new-partnership-302784504.html

SOURCE Playtika Ltd.

New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System

Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) — A new survey from Progyny (Nasdaq: PGNY), a global leader in women’s health and family building solutions, found that people navigating fertility, pregnancy, postpartum, and menopause care increasingly view personalized, human-led healthcare guidance as essential to managing stress and navigating a complex healthcare system.

Among surveyed members, 71% said their healthcare journey added stress to their daily lives, with the top sources including the financial impact of healthcare and treatment, healthcare system complexity, and work/life balance challenges. Patients are not just managing healthcare decisions; they are also managing emotional stress, uncertainty, and mental well-being, all while juggling the everyday demands of work and life. In fact, 43% of respondents said that stress impacted their ability to perform effectively at work.

As Mental Health Awareness Month brings increased attention to the connection between healthcare experiences and emotional well-being, Progyny conducted this survey to better understand the value of human support in an increasingly AI-driven and digital healthcare landscape. The findings showed that more than 70% of respondents said they wish every healthcare experience included knowledgeable and trusted human support, like Progyny Care Advocates® (PCAs). The survey comes at a time when research continues to show that individuals experiencing infertility report levels of anxiety and depression comparable to those facing other serious medical conditions, including cancer and heart disease.

“This research reinforces the importance of human connection and shows that technology alone is not enough, especially during deeply personal and emotional healthcare journeys,” said Dr. Janet Choi, Chief Medical Officer, Progyny. “Patients are looking for more than coverage and digital tools; they want empathy, advocacy, reassurance, and trusted guidance throughout the entire experience. While technology can improve access and efficiency, human support remains one of the most essential components of a cohesive care journey.”

Progyny’s human-led, PCA model connects every member with a dedicated expert trained to proactively provide both clinical and emotional support throughout their healthcare journeys. PCAs help members navigate treatment options, understand benefits coverage, access educational resources, and communicate more effectively with providers, while also serving as a trusted bridge between patients and the complex healthcare system. For many members, PCA support becomes an important source of reassurance during some of the most emotional moments of their care experience.

“My PCA became a trusted source of support who truly knew me, my history, and my journey. When I learned my IUI cycle had not been successful, my PCA immediately called to check in on me, listen, offer encouragement, share mental health resources available to me, and discuss options for treatment next steps to help me navigate what can feel like a marathon of a fertility journey. I felt like I was talking to not only an expert, but also a friend. I’m incredibly thankful for her and for Progyny. It takes a very special person to do this work,” said one Progyny member.

Additional findings from the survey include:

  • 60% of respondents said their interactions with a PCA helped reduce stress related to the care they were seeking
  • Among those respondents, more than 75% said the support Progyny’s PCA team provided significantly helped reduce stress
  • 63% said their PCA helped them feel more educated and empowered in their healthcare journey
  • 54% said their PCA helped them better communicate and self-advocate with providers

Survey respondents included Progyny members navigating fertility, pregnancy and postpartum, and menopause and midlife healthcare journeys.

To learn more about Progyny, visit Progyny.com.

About Progyny

Progyny is a global leader in women’s health and family building solutions, trusted by leading employers, health plans, and benefit purchasers worldwide. Through its comprehensive and personalized approach, Progyny supports members across fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being journeys. Progyny combines differentiated clinical care, integrated pharmacy support through Progyny Rx®, and personalized guidance from Progyny Care Advocates® to deliver improved member experiences and better health outcomes. For more information, visit www.progyny.com.

For Further Information, Please Contact:

Media:
Alexis Ford
[email protected]

Investors:
James Hart
[email protected]



Bansk Group Announces Sale of PetIQ’s Veterinary Services Business to Tractor Supply Company

PR Newswire

Transaction Marks a Key Step in PetIQ’s Evolution into a Leading Branded Pet Health & Wellness Company

NEW YORK, May 28, 2026 /PRNewswire/ — Bansk Group (“Bansk”), a consumer-focused private investment firm dedicated to building distinctive consumer brands, today announced that its portfolio company, PetIQ, Inc. (“PetIQ”), has completed the sale of its veterinary services business, VIP Petcare, to Tractor Supply Company (NASDAQ: TSCO), the largest rural lifestyle retailer in the United States. Financial terms of the transaction were not disclosed.

PetIQ is a leading pet health and wellness company that develops, manufactures and distributes a differentiated portfolio of branded over-the-counter (“OTC”) pet medications and wellness products – including PetArmor®, Capstar®, Nexstar®, Minties®, VetIQ®, and Rocco & Roxie®, among others, available to pet parents through retail and e-commerce channels across more than 60,000 points of distribution nationwide. The sale of VIP Petcare reflects the substantial growth the business has achieved under Bansk’s ownership since 2024, including establishing itself as the nation’s preeminent mobile veterinary care platform.

“Bansk’s strategy is centered around building exceptional brand-led consumer businesses and when we acquired PetIQ, we saw the opportunity to help shape a category leader in pet health and wellness,” said Chris Kelly, Senior Partner of Bansk Group. “Since then, we’ve partnered closely with PetIQ leadership to enhance and scale VIP Petcare into the largest mobile veterinary care business in the country, while also accelerating PetIQ’s vision to become the leading brand-led pet health and wellness company. Tractor Supply’s acquisition is exactly aligned with the outcome our value creation playbook is designed to produce – and it is a reflection of our ability to build distinctive businesses that attract best-in-class strategic acquirers. We look forward to continuing to work with the PetIQ team to accelerate the growth of its core brands and products business, where we see significant runway ahead.”

“This transaction marks an exciting new chapter for PetIQ, and we are well-positioned to realize our full potential as a leading brand-led pet health and wellness company,” said Camillo Pane, Chief Executive Officer of PetIQ. “Bansk’s partnership was instrumental in scaling VIP Petcare into the nation’s preeminent mobile veterinary care business, and this outcome is a testament to what we built together. We are confident in what the team will continue to build as part of Tractor Supply Company.”

William Blair served as financial advisor, and Davis Polk served as legal counsel to Bansk Group and PetIQ. Centerview Partners served as financial advisor, and Sidley Austin served as legal counsel to Tractor Supply.

About Bansk Group

Founded in 2019, Bansk Group is a New York-based private investment firm focused on investing in and building distinctive consumer brands. With over $5 billion in assets under management, the firm partners with differentiated brands across four primary consumer categories: personal care, consumer health, food & beverage, and household products.

Bansk’s tenured group of investors and operators have invested more than $30 billion of equity capital across more than 40 transactions with some of the most innovative and well-known consumer companies in the world. With more than three decades of investment experience in the consumer products industry, a global network of relationships, and a tested value creation playbook, Bansk seeks to partner with exceptional founders and management teams to drive outsized organic and acquisitive growth and to position brands for enduring long-term success in the evolving consumer landscape www.banskgroup.com

About PetIQ

Headquartered in Idaho, PetIQ’s purpose is to champion pet parents in raising healthier, happier pets by delivering smarter pet health and wellness solutions that are innovative, accessible, educational, and always effective. PetIQ specializes in developing, manufacturing, and distributing a diverse portfolio of high-quality, branded medications primarily focused on over-the-counter (“OTC”) flea & tick products, dental treats, and other wellness and nutritional products for companion pets. With brands like PetArmor®, Capstar®, Nextstar®, Minties®, VetIQ®, and Rocco & Roxie® and world-class manufacturing and distribution facilities in Omaha, Nebraska, Springville, Utah and Daytona Beach, Florida, PetIQ is able to deliver trusted solutions to help pets live their best lives, every day.

About Tractor Supply Company

For more than 85 years, Tractor Supply Company (NASDAQ: TSCO) has been passionate about serving the needs of recreational farmers, ranchers, homeowners, gardeners, pet enthusiasts and all those who enjoy living Life Out Here. Tractor Supply is the largest rural lifestyle retailer in the U.S., ranking 296 on the Fortune 500. The Company’s more than 52,000 Team Members are known for delivering legendary service and helping customers pursue their passions, whether that means being closer to the land, taking care of animals or living a hands-on, DIY lifestyle. In store and online, Tractor Supply provides what customers need – anytime, anywhere, any way they choose at the low prices they deserve.

As part of the Company’s commitment to caring for animals of all kinds, Tractor Supply is proud to include Petsense by Tractor Supply, a pet specialty retailer, and Allivet, a leading online pet and animal pharmacy, in its family of brands. Together, Tractor Supply is able to provide comprehensive solutions for pet care, livestock wellness and rural living, ensuring customers and their animals thrive. From its stores to the customer’s doorstep, Tractor Supply is here to serve and support Life Out Here.

As of March 28, 2026, the Company operated 2,435 Tractor Supply stores in 49 states and 206 Petsense by Tractor Supply stores in 23 states. For more information, visit www.tractorsupply.com and www.Petsense.com.

Contacts

Bansk Group
Woomi Yun / Erik Carlson / Madeline Jones
Joele Frank, Wilkinson Brimmer Katcher
+1 212-355-4449

Cision View original content:https://www.prnewswire.com/news-releases/bansk-group-announces-sale-of-petiqs-veterinary-services-business-to-tractor-supply-company-302784502.html

SOURCE Bansk Group